Breast Cancer | Specialty

SOLAR-1 and CBYL719X2101: Alpelisib + Fulvestrant in HR+/HER2-/PIK3CA-Mutated Advanced Breast Cancer

July 9th 2021

Nicholas McAndrew, MD, MSCE, reviews PIK3CA mutations in HR+/HER2- breast cancer and provides his perspective on the joint analysis of SOLAR-1 and CBYL719X2101 in which patients were given alpelisib and fulvestrant.

Survival Advantages in Metastatic Breast Cancer Move the Needle Toward Curative-Intent Strategies

July 8th 2021

Heather L. McArthur, MD, MPH, discusses key advances in breast cancer regarding CDK4/6 inhibitors, PI3K inhibitors, and subcutaneous formulations of standard treatments.

Selecting a CDK4/6 Inhibitor for HR+ mBC

July 7th 2021

Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.

Using CDK4/6 Inhibitors in First-Line Treatment of HR+ mBC

July 7th 2021

A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.

Enobosarm May Represent a Safe, New Hormone Treatment Approach for AR+, ER+ Metastatic Breast Cancer

July 6th 2021

Hannah M. Linden, MD, discusses the potential for enobosarm in patients with metastatic breast cancer, data from a phase 2 trial examining its use, and next steps for the agent in the paradigm.

FDA Supports Continued Development of Oral Paclitaxel/Encequidar in Metastatic Breast Cancer

July 6th 2021

Athenex, Inc. held a Type A meeting with the FDA to discuss the deficiencies raised in the complete response letter issued in March 2021 for the new drug application for oral paclitaxel plus encequidar in the treatment of patients with metastatic breast cancer.

The HER2CLIMB Study in HER2+ MBC

July 6th 2021

The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.

Current Standard of Care for HER2+ MBC

July 6th 2021

Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.

Yale Cancer Center Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers

July 6th 2021

The Future of Breast Cancer Surgery Is Here

July 5th 2021

Thanks to advances in research, targeted therapies, and a more personalized approach to treating patients diagnosed with breast cancer, more surgical options exist for patients with breast cancer patients than ever before.

Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast Cancer

July 1st 2021

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Adjuvant Advances Shine at ASCO 2021

July 1st 2021

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

Management of HR+ mBC: Key Prognostic Factors

June 30th 2021

Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.

Role of Molecular Profiling in HR+ Metastatic Breast Cancer

June 30th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.

Balixafortide Plus Eribulin Fails to Improve ORR in Advanced HER2-Negative Breast Cancer

June 28th 2021

The combination of balixafortide and eribulin did not significantly improve objective response rate over eribulin alone in the treatment of patients with HER2-negative, locally recurrent or metastatic breast cancer, missing the co-primary end point of the phase 3 FORTRESS study.

Internationally Renowned Breast Cancer and HIV-Associated Malignancy Expert to Join Mount Sinai

June 28th 2021

Joseph Sparano, MD, will lead Hematology and Medical Oncology and will be Deputy Director of The Tisch Cancer Institute.

Dr. Pederson on the Importance of Ancestrally-Unbiased Polygenic Risk Assessment in Breast Cancer

June 24th 2021

Holly Pederson, MD, discusses the importance of ancestrally-unbiased polygenic risk assessment in patients with breast cancer.

Dr. Bardia on the Rationale for the AMEERA-5 Trial in ER+/HER2- Breast Cancer

June 24th 2021

Aditya Bardia, MD, MPH, discusses the rationale for the ongoing phase 3 AMEERA-5 trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

June 24th 2021

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Dr. Simons on Racial Disparities Reported in Luminal Breast Cancer

June 22nd 2021

Yael Simons, MD, discusses the racial disparities seen in African Americans patients with luminal breast cancer.